Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Motif Bio launches accelerated book-build placing to raise approximately £10mln to boost iclaprim investments

The AIM-listed biopharmaceutical company said the monies raised will be used to fund near-term regulatory and pre-commercial investments for iclaprim, its novel antibiotic candidate, and to strengthen the company's balance sheet
The cash injection will be used to fund regulatory and pre-commercial investments for iclaprim, its next-generation antibiotic

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) has launched a conditional placing, to raise approximately £10mln (US$14mln), from new and existing investors via an accelerated book-build.

The AIM-listed drug developer company said the monies raised will be used to fund near-term regulatory and pre-commercial investments for iclaprim, its next-generation antibiotic, and to strengthen the company's balance sheet.

READ: Motif Bio makes senior clinical development hire

Graham Lumsden, Motif Bio’s chief executive officer, said: “This funding, along with our existing resources, allows us to fund some regulatory and pre-commercialisation investments for iclaprim and strengthen our balance sheet ahead of entering into more advanced discussions with potential partners to commercialise iclaprim in the U.S. and elsewhere."

iclaprim is being developed to treat acute bacterial skin and skin structure infections (ABSSSI).

It passed a major milestone last year when it successfully concluded a second phase III clinical trial and in March initiated a rolling submission to the US Food and Drug Administration, while also preparing a marketing authorisation application to the European Medicines Agency.

The submission is expected to be completed in the second quarter of 2018.


The drug is a gram-positive antibiotic targeted especially to those who may have impaired kidneys, and/or face other compromising factors, such as diabetes.

It is estimated that up to 26% of the 3.6mln patients hospitalized annually with acute bacterial skin and skin structure infections have kidney disease.

Antibiotics are the most commonly prescribed class of drug, representing a global market of US$40bn. New, innovative approaches are needed, due to ever-evolving drug-resistant strains of bacteria. 

The global market for antibiotic drugs targeting difficult-to-treat infections, such as ABSSSI, is an estimated US$3bln and is dominated by vancomycin, a traditional first-line treatment.


View full MTFB profile View Profile

Motif Bio Plc Timeline

Related Articles

scientist with vial
August 09 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
June 28 2018
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use